Pharma Focus Asia
KP - Sustainable Packaging Solutions

Latest Issue
Get instant access to latest e-book
Repligen

LATEST NEWSRead more...

23

Feb 2024

Rhythm Pharmaceuticals Reveals Clinical Development Strategy for Setmelanotide in Addressing Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Inc a global commercialstage biopharmaceutical company specializing in rare neuroendocrine diseases has announced plans to expand its ongoing global Phase clinical trial

23

Feb 2024

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Ligand Pharmaceuticals Incorporated has announced that Eisai Co Ltd its partner has received approval for the injection formulation of their antiepileptic drug Fycompa

22

Feb 2024

WuXi Advanced Therapies Receives FDA Approval for Manufacturing Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

WuXi Advanced Therapies a subsidiary of WuXi AppTec has received approval from the US Food and Drug Administration to initiate analytical testing and manufacturing of AMTAGVI for Iovance

22

Feb 2024

Dyadic Strengthens Collaboration with Israel Institute for Biological Research (IIBR) to Address Bio-Threats and Emerging Disease Solutions

Dyadic International Inc a prominent biotechnology firm specializing in advanced microbial platforms for protein development and bioproduction has announced a significant advancement

21

Feb 2024

Immuneering's IMM-1-104 Receives FDA Fast Track Designation for Pancreatic Cancer

Immuneering Corporation has recently announced that the US Food and Drug Administration granted Fast Track designation for its lead clinicalstage program IMM targeting patients with pancreatic

21

Feb 2024

Mabwell's Innovative B7-H3 ADC 7MW3711 Receives FDA IND Approval

Mabwell an innovative biopharmaceutical company with a comprehensive industry chain recently announced the approval of its clinical trial application by the US Food and Drug Administration for BH targeting ADC designed for advanced malignant solid tumors

Solovpe

press releasesRead more...

23

Feb 2024

OVID Health launches 2024 Patient Partnership Index showcasing gold standard patient-centric care

Leading independent health communications consultancy OVID Health have announced the opening of their innovative Patient Partnership Index the only international initiative which recognizes

23

Feb 2024

Immunofoco Announces the Dual Approval of IND Applications by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors

Immunofoco a company dedicated to developing cell therapy products for solid tumors announced a significant milestone that following the approval by the CDE in China for the clinical trial application of IMC an EpCAMtargeting autologous CART cell product for infusion

23

Feb 2024

Gracell Biotechnologies Acquisition Completed

Gracell Biotechnologies Inc a global clinicalstage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease today announced the completion of its previously announced agreement to be acquired by Astra

23

Feb 2024

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Elevation Oncology Inc an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical

22

Feb 2024

Everest Medicines’ Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

Everest Medicines partner Pfizer Inc announced that the European Commission has granted marketing authorization for VELSIPITY in the European Union to treat patients years of age and older with

22

Feb 2024

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

Servier a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves today announced the FDA filing acceptance and priority review for a New Drug Application

25 - 27

Feb 2024

26 - 28

Feb 2024

26 - 27

Feb 2024

3rd Rx-to-OTC Switch

Pennsylvania, USA

27 - 28

Feb 2024

29 - 01

Feb 2024

Biomarkers 2024

London, UK

03 - 05

Mar 2024

Saudi Rehab Expo

Riyadh, Saudi Arabia

06 - 07

Mar 2024
Standard BioTools™
MFA + MMA 2024
Gibco Adherent Kidney Media Panel
TFS - ODW - The Technology Debate: Single-Use vs. Stainless Steel
Equinix accelerated medical research...
Thermofisher - Antibody Therapeutic Polishing
Searching for an end-to-end patient tech solution?

TOP ARTICLES

  • 1

    Incipient Biopharmaceutical Claims of Milk Derived Exosomes

    Rakesh Kumar Tekade

    Associate Professor, NIPER-Ahmedabad

    Nupur Vasdev

    Pursuing PhD in Pharmaceutics, NIPER-Ahmedabad

    Manisha Choudhary

    Pursuing M.S. (Pharm) in Pharmaceutics, NIPER-Ahmedabad

    Suryanarayana Polaka

    Pursuing PhD, NIPER-Ahmedabad

    Kiran Kalia

    Director and Professor, NIPER-Ahmedabad

  • 5

    3D Printing Revolutionising Nanotechnology

    Mansi Athalye

    Assistant Professor , Department of Pharmaceutics at L. M. College of Pharmacy

    Sagar Popat

    Research Student, Pursuing M. Pharmacy, Pharmaceutics, L. M. College of Pharmacy

KNOWLEDGE BANK

  • Interviews

    Innovation Management at Bachem

    Chief Technology Officer, Bachem Holding AG

    Gnther Loidl joined Bachem in He held several functions in Research and Development RD and Active Pharmaceutical Ingredient Manufacturing and became Vice President RD in Since he is CTO of the Bachem Group and a member of the Corporate Executive Committee He studied chemistry in Regensburg Germany and Leeds UK and obtained his doctorate under the supervision of Luis Moroder at the Max Planck In...
  • Articles

    Smart Polymeric Nanocomposites for Cancer Therapeutics

    Globally cancer is the second most prevalent healthcare issue following cardiovascular Conventional methods such as chemotherapy and radiotherapy have several detrimental side effects without guaranteed permanent recovery In the last few decades efforts have been made by introducing nanotechnology to cancer therapeutics

EDITORIAL SECTION